Other Income & Expense
Other Income (Expense)
Royalty Pharma Other Income (Expense) decreased by 191.9% to -$94.78M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from -$99.75M to -$94.78M. Over 3 years (FY 2021 to FY 2025), Other Income (Expense) shows a downward trend with a 7.3% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Detailed definition
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Peer comparison
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
Metric ID:
other_income_expense_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $61.81M | -$81.26M | -$99.75M | -$91.64M | $113.81M | $28.20M | -$127.38M | $30.12M | $102.50M | -$29.37M | $104.69M | $69.50M | -$75.25M | $71.28M | -$99.75M | -$119.16M | $17.06M | -$32.47M | -$94.78M |
| QoQ Change | — | -231.5% | -22.8% | +8.1% | +224.2% | -75.2% | -551.6% | +123.6% | +240.3% | -128.6% | +456.5% | -33.6% | -208.3% | +194.7% | -239.9% | -19.5% | +114.3% | -290.4% | -191.9% |
| YoY Change | — | — | — | — | +84.1% | +134.7% | -27.7% | +132.9% | -9.9% | -204.1% | +182.2% | +130.8% | -173.4% | +342.8% | -243.5% | -58.4% | -76.1% | — | +5.0% |
Range-$127.38M – $113.81M
CAGR+10.0%
Avg YoY Growth+15.7%
Median YoY Growth-2.5%
Current Streak2 quarters decline
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's other income (expense)?
- Royalty Pharma (RPRX) reported other income (expense) of -$94.78M in Q1 2026.
- How has Royalty Pharma's other income (expense) changed year-over-year?
- Royalty Pharma's other income (expense) increased by 5.0% year-over-year, from -$99.75M to -$94.78M.
- What is the long-term trend for Royalty Pharma's other income (expense)?
- Over 3 years (2021 to 2025), Royalty Pharma's other income (expense) has grown at a 7.3% compound annual growth rate (CAGR), from -$189.51M to -$234.33M.
- What does other income (expense) mean?
- The net result of all income and expenses not related to core business operations.